🗞
Medical Articles Source: PubMed
Topic: Shorter oral regimens show promise for rifampin-resistant tuberculosisA phase 3 multinational trial evaluated five 9-month oral regimens for fluoroquinolone-susceptible, rifampin-resistant TB against standard therapy. Four regimens—BCLLfxZ, BLMZ, BDLLfxZ, and DCMZ—were noninferior, though DCMZ did not meet criteria in the per-protocol analysis. Adverse events were comparable across groups, with hepatotoxicity occurring in 11.7%. These findings support shorter, all-oral regimens as effective alternatives, potentially improving adherence and reducing treatment burden.
https://pubmed.ncbi.nlm.nih.gov/39879593/@HakimApps_Guideline